14 Jan 2013 07:00
For immediate release | 14 January 2013 |
Futura Medical PLC
("Futura" or the "Company")
Notification of Preliminary Results
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will announce its preliminary results for the year ended 31 December 2012 on Thursday 7 March 2013.
A briefing for analysts will be held at 10.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London, EC2V 6DN.
For more information, or to register attendance, please contact Buchanan on 020 7466 5000.
For further information:
Futura Medical plc | + 44 (0) 1483 685 670 |
James Barder, Chief Executive Officer | |
Mail to: James.Barder@futuramedical.com | www.futuramedical.com |
Nomura Code Securities Limited | + 44 (0) 20 7776 1200 |
Phil Walker / Giles Balleny | |
| |
Buchanan | + 44 (0) 20 7466 5000 |
Mark Court / Fiona Henson / Sophie Cowles |
Notes to editors:
About Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Futura Medical (FUM)